BrightPath Biotherapeutics Co., Ltd.
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
BrightPath Biotherapeutics Co., Ltd. made a loss over the last year. BrightPath Biotherapeutics Co., Ltd. owes ¥0.10 for every ¥1 it owns. BrightPath Biotherapeutics Co., Ltd. made a loss in each of the last two years.
Compared with Healthcare companies in Japan · latest annual results Mar 2026.
P/E ratio
LossBrightPath Biotherapeutics Co., Ltd. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.12The share price is 3.12 times BrightPath Biotherapeutics Co., Ltd.'s book value per share, higher than 80% of Healthcare companies in Japan.
Market cap
¥5.7 BThe total market value of all of BrightPath Biotherapeutics Co., Ltd.'s shares at today's price (share price × number of shares), smaller than 77% of Healthcare companies in Japan. PosiCap size class: Micro Cap.
Net worth (book value)
¥1.8 BWhat BrightPath Biotherapeutics Co., Ltd. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
¥13.12Net worth divided by the number of shares. The share price of ¥41.00 is 3.1 times this, which is the P/B above.
Return on equity (ROE)
-79.2%BrightPath Biotherapeutics Co., Ltd. lost 79.2% of its shareholders' money over the last year, lower than 95% of Healthcare companies in Japan.
Owes vs Owns
0.10×BrightPath Biotherapeutics Co., Ltd. owes ¥0.10 for every ¥1 it owns (low), lower than 92% of Healthcare companies in Japan.
Dividend yield
NoneBrightPath Biotherapeutics Co., Ltd. does not currently pay a dividend.
Revenue growth
-93%Revenue fell 93% in the year to Mar 2026, and shrank 75% a year on average over 3 years.
Profit growth
LossBrightPath Biotherapeutics Co., Ltd. made a loss in each of the last two years.
Profit margin
-1553513.1%BrightPath Biotherapeutics Co., Ltd. lost ¥1553513 for every ¥100 of revenue.
Cash vs debt
Net cashBrightPath Biotherapeutics Co., Ltd. held ¥2.2 B more cash than debt (net cash) at Mar 2026.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For BrightPath Biotherapeutics Co., Ltd.: ¥5.7 B ÷ ¥1.8 B (30 Jun 2026) = 3.1.
What is BrightPath Biotherapeutics Co., Ltd.'s return on equity?
BrightPath Biotherapeutics Co., Ltd. lost 79.2% of its shareholders' money over the last year, lower than 95% of Healthcare companies in Japan.
How much does BrightPath Biotherapeutics Co., Ltd. owe compared with what it owns?
BrightPath Biotherapeutics Co., Ltd. owes ¥0.10 for every ¥1 it owns (low), lower than 92% of Healthcare companies in Japan.
Does BrightPath Biotherapeutics Co., Ltd. pay a dividend?
No. BrightPath Biotherapeutics Co., Ltd. does not currently pay a dividend.
Is BrightPath Biotherapeutics Co., Ltd.'s revenue growing?
Revenue fell 93% in the year to Mar 2026, and shrank 75% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.